Literature DB >> 32292538

Psilocybin Therapeutic Research: The Present and Future Paradigm.

Robert B Kargbo1.   

Abstract

Psilocybin, an active component in "magic mushroom", may have the potential to meet the therapeutic needs for a number of indications without the addictiveness and overdose risk of other mind-altering drugs, such as cocaine, heroin, alcohol, methamphetamine, and so forth. The need for new therapies is urgent because addiction, overdose, and suicide deaths have risen throughout the United States and around the world. Anecdotal and contemporary pharmacological reports have provided some indication about the therapeutic use of psilocybin for the treatment of mental health disorders such as major depressive disorder and addiction disorders. In this Viewpoint, I summarize the current state of psilocybin therapeutic research and attempt to provide some insight into future directions on which the scientific community may wish to focus.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32292538      PMCID: PMC7153026          DOI: 10.1021/acsmedchemlett.0c00048

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  9 in total

1.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  J Psychopharmacol       Date:  2012-03-08       Impact factor: 4.153

Review 2.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Authors:  Franz X Vollenweider; Michael Kometer
Journal:  Nat Rev Neurosci       Date:  2010-08-18       Impact factor: 34.870

3.  Drug harms in the UK: a multicriteria decision analysis.

Authors:  David J Nutt; Leslie A King; Lawrence D Phillips
Journal:  Lancet       Date:  2010-10-29       Impact factor: 79.321

4.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

Review 5.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

6.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

Review 8.  Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature.

Authors:  Timothy I Michaels; Jennifer Purdon; Alexis Collins; Monnica T Williams
Journal:  BMC Psychiatry       Date:  2018-07-31       Impact factor: 3.630

Review 9.  Development of a rational scale to assess the harm of drugs of potential misuse.

Authors:  David Nutt; Leslie A King; William Saulsbury; Colin Blakemore
Journal:  Lancet       Date:  2007-03-24       Impact factor: 79.321

  9 in total
  7 in total

Review 1.  An Update on the Implications of New Psychoactive Substances in Public Health.

Authors:  Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo
Journal:  Int J Environ Res Public Health       Date:  2022-04-17       Impact factor: 4.614

Review 2.  Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders.

Authors:  Nataliya Vorobyeva; Alena A Kozlova
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

3.  Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines.

Authors:  Claudius Lenz; Sebastian Dörner; Felix Trottmann; Christian Hertweck; Alexander Sherwood; Dirk Hoffmeister
Journal:  Chembiochem       Date:  2022-05-18       Impact factor: 3.461

4.  Genetic Survey of Psilocybe Natural Products.

Authors:  Sebastian Dörner; Kai Rogge; Janis Fricke; Tim Schäfer; Jacob M Wurlitzer; Markus Gressler; Duyen N K Pham; David R Manke; Andrew R Chadeayne; Dirk Hoffmeister
Journal:  Chembiochem       Date:  2022-06-09       Impact factor: 3.461

Review 5.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

6.  Identification of the Antidepressant Function of the Edible Mushroom Pleurotus eryngii.

Authors:  Yong-Sung Park; Subin Jang; Hyunkoo Lee; Suzie Kang; Hyewon Seo; Seoyeong Yeon; Dongho Lee; Cheol-Won Yun
Journal:  J Fungi (Basel)       Date:  2021-03-08

Review 7.  Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy.

Authors:  Sascha B Thal; Stephen J Bright; Jason M Sharbanee; Tobias Wenge; Petra M Skeffington
Journal:  Front Psychol       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.